NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
Clinical Trials
11 trialsNCT05469750 2022-07-22
Dalpiciclib Plus Letrozole and Capecitabine
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05439499 2022-07-06
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05438810 2022-07-05
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03071926 2022-04-20
Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Fudan University
Phase 2 Unknown
NCT05255523 2022-02-24
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer
Fujian Medical University Union Hospital
Phase 2 Unknown
NCT05156619 2022-01-25
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Hadassah Medical Organization
Unknown
NCT05047848 2021-09-17
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
Liaoning Cancer Hospital & Institute
Phase NA Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT01311037 2011-12-13
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
King Faisal Specialist Hospital & Research Center
Unknown
NCT00874146 2010-09-02
Level of HER2-neu Gene Amplification an Response to Trastuzumab
Istituto Clinico Humanitas
Unknown